Saturday, 31 October 2026European Markets

ALTUR INVEST. Stock 15.96% Up On Thursday

Loading stream...

(vianews) - the market ended the session with altur invest. (altur.pa) rising 15.96% to €10.90 on thursday while cac 40 jumped 0.24% to €7,277.93.

about altur invest.

altur investissement sca, scr specializes in buyouts, including leveraged buyouts and owner buyouts, and growth capital investments in small and medium enterprises. it seeks to invest in health, internet, sustainable development, distribution, industrials, hotel industry, and services. it only invests in private companies. the fund seeks to invest in businesses with a maximum enterprise value of €100 million ($128 million). it can be the sole or leading investor. it prefers to take majority and minority stakes in its portfolio companies. the funds strategy is to invest over an unlimited period of time.

earnings per share

as for profitability, altur invest. has a trailing twelve months eps of €0.36.

pe ratio

altur invest. has a trailing twelve months price to earnings ratio of 30.28. meaning, the purchaser of the share is investing €30.28 for every euro of annual earnings.

volume

today's last reported volume for altur invest. is 103323 which is 7338.66% above its average volume of 1389.

more news about altur invest. (altur.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com